Close to 120 companies across the globe claim to possess the required expertise and infrastructure to offer contract manufacturing services for HPAPIs and cytotoxic drugs, claims Roots Analysis
Development initiatives of HPAPIs and cytotoxic drugs are generally very demanding, both in terms of experience and capital investment. Most companies generally lack the necessary resources to meet the aforementioned requirements and are unable to set up dedicated HPAPI and cytotoxic drug manufacturing facilities. This has led to an increased demand for contract manufacturing service providers in this field.
To order this 300+ page report, which features 75+ figures and 150+ tables, please visit this link
The USD 25 billion (by 2030) financial opportunity within the HPAPI and cytotoxic drugs contract manufacturing market has been analyzed across the following segments:
- Type of Product
- HPAPIs
- Highly Potent Finished Dosage Forms
- Company Size
- Small-sized
- Mid-sized
- Large / Very Large
- Scale of Operation
- Preclinical / Clinical
- Commercial
- Type of Pharmacological Molecule
- Small Molecules
- Biologics
- Type of Highly Potent Finished Dosage Form
- Injectables
- Oral Solids
- Creams
- Others
- Key geographical regions
- North America
- Europe
- Asia Pacific
- Rest of the World
The “HPAPI and Cytotoxic Drugs Manufacturing (3rd Edition) 2020-2030” report features the following companies, which we identified to be key players in this domain:
- AbbVie Contract Manufacturing
- CARBOGEN AMCIS
- Catalent
- Evonik
- Formosa Laboratories
- Intas
- Lonza
- MabPlex
- Pfizer CentreOne
Table of Contents
1. Preface
2. Executive Summary
3. Introduction
4. Market Landscape
5. Company Competitive Analysis
6. HPAPI and Cytotoxic Drugs Contract Manufacturers based in North America: Company Profiles
7. HPAPI and Cytotoxic Drugs Contract Manufacturers based in Europe: Company Profiles
8. HPAPI and Cytotoxic Drugs Contract Manufacturers based in Asia Pacific: Company Profiles
9. Partnerships and Collaborations
10. Recent Expansions
11. Capacity Analysis
12. Market Sizing and Opportunity Analysis
13. Case-In-Point: Contract Manufacturing of Antibody Drug Conjugates
14. Concluding Remarks
15. Executive Insights
16. Appendix 1: Tabulated Data
17. Appendix 2: List of Companies and Organizations
To purchase a copy, please visit https://www.rootsanalysis.com/reports/view_document/hpapi-and-cytotoxic-drugs-manufacturing/299.html
Contact Details
Gaurav Chaudhary
+1 (415) 800 3415
gaurav.chaudhary@rootsanalysis.com